Lysa
19 June 2018
LYSA’s RELEVANCE Trial in the Media
Return on the presentation of Franck Morschhauser, from Claude Huriez Hospital (Lille, France), president of the LYSA scientific committee, on the interim results obtained for the phase III clinical trial RELEVANCE.
Please, discover the press release on this study, published on the website of ASHand the video made by ecancer!
Reference: Franck Morschhauser et al. Relevance : Phase III Efficacity and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma.
News
23 May 2022 Lysa
LYSA studies presented during 2022 ASCO and E...
2 oral communications an 4 posters presented by LYSA in the program of thes...
16 May 2022 Lysa
Health’s Broadcast Magazine de la santé &#...
The reference health broadcast called Le Magazine de la santé on France 5,...
21 November 2021 Lysa
LYSARC – Review of the 2020 Assessment ...
LYSARC - 2020 Review and outlook for 2021